Axis Mutual Fund increased its stake in IPCA Laboratories from 1.83% to 1.94%, buying 2,78,227 shares at ₹1920.40 apiece, for a total value of ₹53.43 Cr.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
Subsidiary of Axis Bank, India's third-largest private sector bank. Manages over Rs 3.5 lakh crore in AUM. Built its brand on a quality growth equity philosophy with concentrated high-conviction portfolios. Flagship Axis Flexi Cap and Axis Bluechip funds are widely held among retail investors and drove significant AUM growth through the 2017-2021 bull cycle.